Glaxosmithkline Biologicals Sa

Fabio Serventi

Michael T Kowarik

Amirreza Faridmoayer

Stefan Jochen Kemmler

Rainer Follador

Gerald Johann Posch

Gerd Martin Lipowsky

A process for engineering a host cell comprising the steps of a) integrating a first polynucleotide cassette including a first selection marker flanked by a first pair of recombination sites; b) removing the first selection marker by the action of a recombinase which recognises the first pair of recombination sites; c) integrating a second polynucleotide cassette including a second selection marker flanked by a second pair of recombination sites; and d) removing the second selection marker by the action of a recombinase which recognises the second pair of recombination sites. The first and second pairs of recombination sites have identical nucleic acid sequences within each pair, sharing 90-98% nucleic acid sequence identity. Also disclosed is a host cell genome polynucleotide comprising two recombinantly engineered regions, each adjacent to a single recombination site sharing 90-98% identity with each other and any additional recombination sites present in the host cell genome polynucleotide.

Process for the manipulation of nucleic acids

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by

Immunogenic composition

The present invention discloses a process for engineering a host cell comprising the steps of; a) integrating a first polynucleotide cassette including a first selection marker flanked by a first pair of recombination sites; b) removing the first selection marker by the action of a recombinase which recognises the first pair of recombination sites; c) integrating a second polynucleotide cassette including a second selection marker flanked by a second pair of recombination sites; and d) removing the second selection marker by the action of a recombinase which recognises the second pair of recombination sites. Also disclosed is a host cell genome polynucleotide comprising a first recombinantly engineered region and a second recombinantly engineered region, wherein a first single recombination site is adjacent to the first recombinantly engineered region, and a second single recombination site is adjacent to the second recombinantly engineered region.

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;3)-[[&#x3b1;-L-Rhap-(1&#x2192;2)]-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)]-&#x3b2;-L-Rhap-(1&#x2192;. Also provided are conjugates comprising a &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;3)-[[&#x3b1;-L-Rhap-(1&#x2192;2)]-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)]-&#x3b2;-L-Rhap-(1&#x2192;, immunogenic compositions, vaccines and their use in preventing or treating infection by

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;4)-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)-&#x3b2;-L-Rhap-(1&#x2192;. Also provided are conjugates comprising a &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;4)-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)-&#x3b2;-L-Rhap-(1&#x2192;, immunogenic compositions, vaccines and their use in preventing or treating infection by

Growing community of inventors

Schlieren, Switzerland

Fabio Serventi